Corvus Pharmaceuticals IncCRVS
Price$10.93

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$54.1MTTM through 30 Jun 2026
Free Cash Flow -$45.2MTTM through 30 Jun 2026

Margins

Current

Returns

-30.4%ROE
-28.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio20.26x
Net Debt-$235.9Mnet cash position
Cash & Equivalents$18.9M

Quality Metrics

Altman Z-Score46.30
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$0.62TTM
'19'20'21'22'23'24'25
FY2025: $-0.19

Dividend

No dividend

Capital Allocation

R&D Spend$45.5M

Segment Performance

SegmentRevenueYoYOutlook
Clinical-stage Biopharmaceuticals$0
View details

The company operates as a single reportable segment focused on the development of ITK inhibitors and other immunotherapies.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.